Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

New Agent Found to Suppress Cognitive Impairment of Alzheimer’s Disease

By BiotechDaily International staff writers
Posted on 25 Nov 2013
Print article
A unique new compound has been shown to prevent cognitive impairment and oxidative stress in animal lab models and may ultimately be useful in treating Alzheimer’s disease (AD).

This new findings on the compound, IRL-1620, were presented at the 2013 American Association of Pharmaceutical Scientists (AAPS) annual meeting and exposition, the world’s largest pharmaceutical sciences meeting, held in San Antonio (TX, USA), November 10-14, 2013.

Anil Gulati, MD, PhD, FCP, and Seema Briyal, PhD, along with their colleagues from Midwestern University (Downers Grove, IL, USA), administered Amyloid beta (Aβ), a key component of specific deposits located in AD patients’ brains, to normal and diabetic rats on days 1, 7, and 14. The lab rat’s spatial learning and memory were assessed in a Morris water maze. The pool was separated into four equal quadrants, and an escape platform was hidden below the surface at a fixed location in one of the quadrants.

The rats had to locate the platform within 60 seconds. The average time it took on day 4 for Aβ-treated rats to locate the platform was 55.05 seconds, though most of this group was not able to find it in the allotted time. Aβ rats treated with IRL-1620 were able to find the platform in 26.53 seconds, nearly 50% the time. After five days, Aβ rats treated with IRL-1620 showed a 60% improvement in learning and memory.

“Our research is based on the idea of using the endothelin [ET] system in the treatment of AD,” said Dr. Gulati. “The ET system is traditionally known to play a role in the regulation of blood flow. This is important in the potential treatment of AD since disturbances in blood flow could damage the brain’s ability to clear damaging particles, leading to a buildup of toxic substances and cognitive impairment.”

The next stage of the research is to additionally study the endothelin receptor type B’s mechanisms of neuroprotection and to look into possible resulting tissue changes following AD.

The US Food and Drug Administration (FDA) has approved five medications to treat the symptoms of AD. Current agents help disguise the symptoms but do not treat the underlying disease. A breakthrough AD treatment would target the underlying disease and stop or delay the cell damage that ultimately leads to the aggravation of symptoms.

Related Links:

Midwestern University



Print article

Channels

Genomics/Proteomics

view channel
Image: An expression of NOTCH 1 (green color) in ACC stem cells (Photo courtesy of Yale University).

Adenoid Cystic Carcinoma Stem Cells Depend on NOTCH1 and SOX10 Signaling

Cancer researchers have isolated a stem cell population from the cells making up an adenoid cystic carcinoma (ACC) tumor and showed that the signaling factors NOTCH1 and SOX10 were essential for the cancer... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.